Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) Using Multiplex Proteomics Technology

Early detection of pancreatic ductal adenocarcinoma (PDAC) can improve survival but is hampered by the absence of early disease symptoms. Imaging remains key for surveillance but is cumbersome and may lack sensitivity to detect small tumors. CA19-9, the only FDA-approved blood biomarker for PDAC, is...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Alcibiade Athanasiou (4325797) (author)
مؤلفون آخرون:	Natasha Kureshi (19673245) (author), Anja Wittig (8856431) (author), Maria Sterner (20454325) (author), Ramy Huber (8856434) (author), Norma A. Palma (17529744) (author), Thomas King (4446796) (author), Ralph Schiess (727375) (author)
منشور في:	2024
الموضوعات:	Biochemistry Cell Biology Genetics Molecular Biology Pharmacology Immunology Cancer Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified roughly 3000 proteins pancreatic ductal adenocarcinoma imaging remains key detect small tumors based protein signature onset diabetes (< chronic pancreatitis (< early disease symptoms signatures significantly (< may lack sensitivity approved blood biomarker 50 ), individuals improve pdac detection early detection pdac (< plex signatures improve survival biomarker discovery 47 ), target population p </ n </ insufficiently sensitive independent cohort high risk exploratory analysis conventional immunoassays 36 ).
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) Using Multiplex Proteomics Technology

مواد مشابهة